Owing to their pleiotropic metabolic benefits, glucagon-like peptide-1 receptor (GLP-1R) agonists have been successfully utilized for treating metabolic diseases, such as type 2 diabetes and obesity. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.